1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Pulmonary Tuberculosis - Pipeline Review, H2 2014

Pulmonary Tuberculosis - Pipeline Review, H2 2014

  • September 2014
  • -
  • Global Markets Direct
  • -
  • 63 pages

Pulmonary Tuberculosis - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Pulmonary Tuberculosis - Pipeline Review, H2 2014’, provides an overview of the Pulmonary Tuberculosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Tuberculosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Tuberculosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pulmonary Tuberculosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pulmonary Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pulmonary Tuberculosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Tuberculosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pulmonary Tuberculosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Pulmonary Tuberculosis - Pipeline Review, H2 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Pulmonary Tuberculosis Overview 7
Therapeutics Development 8
Pipeline Products for Pulmonary Tuberculosis - Overview 8
Pipeline Products for Pulmonary Tuberculosis - Comparative Analysis 9
Pulmonary Tuberculosis - Therapeutics under Development by Companies 10
Pulmonary Tuberculosis - Therapeutics under Investigation by Universities/Institutes 11
Pulmonary Tuberculosis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Pulmonary Tuberculosis - Products under Development by Companies 15
Pulmonary Tuberculosis - Products under Investigation by Universities/Institutes 16
Pulmonary Tuberculosis - Companies Involved in Therapeutics Development 17
Johnson and Johnson 17
Sequella, Inc. 18
AstraZeneca PLC 19
Microbion Corporation 20
Pulmonary Tuberculosis - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
bedaquiline fumarate - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
SQ-109 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
SQ-109 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
sutezolid - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
posizolid - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
pretomanid - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
pulmonary tuberculosis + leprosy vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
SQ-609 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
r30 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
methionine sulfoximine - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
Small Molecule for Pneumonia, COPD, Cystic Fibrosis and Pulmonary Tuberculosis - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
Pulmonary Tuberculosis - Recent Pipeline Updates 51
Pulmonary Tuberculosis - Dormant Projects 56
Pulmonary Tuberculosis - Product Development Milestones 57
Featured News and Press Releases 57
Dec 20, 2013: SIRTURO Receives Positive Opinion from the Committee for MedicinalProducts for Human Use as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant Tuberculosis 57
Jul 26, 2013: Otsuka Receives Opinion from CHMP on Delamanid 57
Jul 02, 2012: Janssen Submits New Drug Application To FDA For Bedaquiline For Multi-Drug Resistant Tuberculosis Treatment 58
Oct 18, 2010: Sequella Receives International Support For Phase II Clinical Trials Of SQ109 For Treatment Of Adult Pulmonary Tuberculosis 59
Oct 18, 2005: The Global Alliance for TB Drug Development Announces Phase II Trials To Study Potential Of Moxifloxacin To Shorten TB Treatment Partners Commit To Affordable Pricing For Patients In The Developing World 60
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 63
Disclaimer 63

List of Tables

Number of Products under Development for Pulmonary Tuberculosis, H2 2014 8
Number of Products under Development for Pulmonary Tuberculosis - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Pulmonary Tuberculosis - Pipeline by Johnson and Johnson, H2 2014 17
Pulmonary Tuberculosis - Pipeline by Sequella, Inc., H2 2014 18
Pulmonary Tuberculosis - Pipeline by AstraZeneca PLC, H2 2014 19
Pulmonary Tuberculosis - Pipeline by Microbion Corporation, H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Assessment by Combination Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 30
Pulmonary Tuberculosis Therapeutics - Recent Pipeline Updates, H2 2014 51
Pulmonary Tuberculosis - Dormant Projects, H2 2014 56

List of Figures

Number of Products under Development for Pulmonary Tuberculosis, H2 2014 8
Number of Products under Development for Pulmonary Tuberculosis - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Products, H2 2014 14
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Top 10 Target, H2 2014 23
Number of Products by Stage and Top 10 Target, H2 2014 24
Number of Products by Top 10 Mechanism of Action, H2 2014 25
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 26
Number of Products by Top 10 Route of Administration, H2 2014 27
Number of Products by Stage and Top 10 Route of Administration, H2 2014 28
Number of Products by Top 10 Molecule Type, H2 2014 29
Number of Products by Stage and Top 10 Molecule Type, H2 2014 30

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.